Cogent Biosciences now has three bezuclastinib NDAs under FDA review
Cogent now has three bezuclastinib NDAs under FDA review, with GIST and non-advanced mastocytosis decisions due before year-end.
Pharma & Biotech
Pharma & Biotech
Cogent advances third bezuclastinib FDA submission after APEX pivotal trial results
Cogent’s bezuclastinib NDA for advanced systemic mastocytosis is backed by APEX data showing 65% ORR and deep KIT-driven disease marker reductions.
Pharma & Biotech
How Cogent Biosciences, Inc.’s bezuclastinib filing could redefine the second-line treatment paradigm in gastrointestinal stromal tumors
Cogent Biosciences files bezuclastinib NDA in second-line GIST. Explore what the PEAK data could change for clinicians, regulators, and investors.